The present invention refers to a procedure for treating binary substances, involving the management of an estrogen component, preferably selected from a group of stars and star compounds. Surprisingly, stellar compounds can alleviate deoxyribonucleic acid to a greater extent than other compounds and safety effects described, whether used alone or in combination with congenital components. Compared with existing procedures, the Technology Development and Transfer Board has proposed inventions related to the management methods of technology transfer.SMENRHEA involves administration of an estrogenic component which is preferably selected from the group consisting of estetrol and estetrol-like compounds. Estetrol-like compounds have been surprisingly found to be capable of mitigating dysmonorrheaEither when used alone or in combination with proestogenic components, and this to an extent surpass the effect obtained with other compositions and with a favourable side-effect profile compared to currently available methods.La presente invención se refiere a un procedimiento para el tratamiento de la dismenorrea que implica la administración de un componente estrógeno que se selecciona preferentemente del grupo que consiste en estetrol y compuestos de tipo estetrol. Se ha descubierto sorprendentemente que los compuestos de tipo estetrol son capaces de mitigar la dismenorrea, bien cuando se usan solos o bien en combinación con componentes progestágenos, y esto en una medida que supera el efecto obtenido con otras composiciones y con un perfil de efectos secundarios favorable en comparación con procedimientos disponibles en la actualidadThe present invention relates to a method for the management of dysmenorrhea involving administration of an estrogenic component which is preferably selected from the group consisting of estetrol and estetrol-like compounds. Estetrol-like compounds have been surprisingly found to be capable of mitigating dysmenorrhea, either when used alone or
